Hologic, Inc. (NASDAQ:HOLX) Director Namal Nawana purchased 6,600 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was bought at an average cost of $37.88 per share, with a total value of $250,008.00. Following the completion of the acquisition, the director now owns 6,954 shares of the company’s stock, valued at $263,417.52. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Hologic, Inc. (NASDAQ:HOLX) traded up $0.23 during trading hours on Wednesday, hitting $38.03. The stock had a trading volume of 3,320,590 shares, compared to its average volume of 3,012,295. The stock has a market capitalization of $10,519.17, a P/E ratio of 10.03, a P/E/G ratio of 1.72 and a beta of 0.77. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25. Hologic, Inc. has a twelve month low of $35.33 and a twelve month high of $46.80.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.05. The business had revenue of $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.52 earnings per share. research analysts forecast that Hologic, Inc. will post 2.25 earnings per share for the current year.
A number of equities analysts have recently weighed in on the company. Canaccord Genuity reissued a “buy” rating and issued a $48.00 price target on shares of Hologic in a report on Friday, February 9th. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Hologic in a report on Friday, February 9th. Stifel Nicolaus cut Hologic from a “buy” rating to a “hold” rating and cut their price target for the stock from $45.00 to $42.00 in a report on Friday, February 9th. Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a report on Tuesday. Finally, Royal Bank of Canada reissued a “hold” rating and issued a $44.00 price target on shares of Hologic in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $48.00.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.